Chemomab Therapeutics (CMMB) Capital Expenditures (2018 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Capital Expenditures came in at $6000.0 in Q4 2023, down 95.56% YoY from $135000.0 in Q4 2022, and up 250.0% on a QoQ basis from -$4000.0 in Q2 2023.
Chemomab Therapeutics (CMMB) Capital Expenditures (2018 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 6 years of Capital Expenditures data on file, last reported at $6000.0 in Q4 2023.
- Quarterly Capital Expenditures fell 95.56% year-over-year to $6000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3000.0 (down 95.59% YoY) and the FY2025 annual result came in at $3000.0, changed N/A from the prior year.
- Capital Expenditures grew to $6000.0 in Q4 2023, from -$4000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $255000.0 in Q3 2019 to a low of -$1.3 million in Q4 2019.
- A 5-year average of -$34833.3 and a median of $6500.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2019 — Capital Expenditures sank 430.25% — and 2021, when it surged 13300.0%.
- Tracing CMMB's Capital Expenditures over 5 years: stood at -$1.3 million in 2019, then jumped by 100.08% to $1000.0 in 2020, then surged by 13300.0% to $134000.0 in 2021, then increased by 0.75% to $135000.0 in 2022, then sank by 95.56% to $6000.0 in 2023.
- The last three Capital Expenditures figures came in at $6000.0 (Q4 2023), -$4000.0 (Q2 2023), and $1000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Chemomab Therapeutics | 13.52 Mn | 3.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 6,000.00 |
| Dec 31, 2023 | 6,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Dec 31, 2022 | 135,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Sep 30, 2022 | -42,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Jun 30, 2022 | -39,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Dec 31, 2021 | 134,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Jun 30, 2021 | 102,000.00 |
| Mar 31, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |